The Florida Surgeon General is calling for a halt in the use of mRNA COVID-19 vaccines due to concerns about their safety. Dr. Joseph Ladapo has criticized the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) for not adequately testing the vaccines for DNA integration with the human genome, as their own guidelines recommend. He argues that the vaccines are contaminated with foreign DNA, which poses a risk to human health.
In a letter to FDA Commissioner Robert Califf and then-CDC Director Rochelle Walensky, Ladapo expressed his discontent with the agencies' disregard for the risks associated with mRNA COVID-19 vaccines and accused them of manipulating the public into believing that the vaccines are harmless. He believes that this has led to a deep distrust in the American healthcare system.
Ladapo further raised concerns about the presence of DNA fragments in the Pfizer and Moderna COVID-19 mRNA vaccines in a subsequent letter to Califf and CDC Director Mandy Cohen. He emphasized that these fragments could potentially integrate into the chromosomal DNA of cells, including sperm or egg gametes, and be passed on to future generations.
However, in response to Ladapo's concerns, Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, defended the safety and effectiveness of the COVID-19 vaccines. Marks stated that with over a billion doses administered, no safety concerns related to residual DNA have been identified. He argued that it is highly unlikely for small DNA fragments in the cytosol to enter the nucleus of intact cells and integrate into chromosomal DNA.
Despite this response, Ladapo is now calling for a halt in the usage of mRNA COVID-19 vaccines. He believes that the risk of DNA integration poses a significant threat to human health and the integrity of the human genome. According to a press release from the Florida Department of Health, Ladapo suggests that healthcare providers prioritize the use of non-mRNA COVID-19 vaccines and treatment for patients concerned about the associated risks.
